MIRA Pharmaceuticals, Inc. (MIRA) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Drug Manufacturers - General
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
7.02
+13% vs avg
5yr avg: 6.23
30Y Low4.5·High8.0
ROE
↓
-238.9%
↓+50% vs avg
5yr avg: -479.9%
30Y Low-239%·High-198%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MIRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MIRA Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $40M | $18M | $19M | — | — | — |
| Enterprise Value | $37M | $15M | $15M | — | — | — |
| P/E Ratio → | -1.96 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 7.02 | 8.00 | 4.46 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MIRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
MIRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -238.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -238.9% | -238.9% | -634.3% | -847.8% | -198.5% | — |
| ROA | -199.9% | -199.9% | -413.9% | -335.0% | -128.9% | -303.9% |
| ROIC | — | — | — | — | — | — |
| ROCE | -243.9% | -243.9% | -441.5% | -805.8% | -196.2% | — |
MIRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $3M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | — | 0.13 | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.29 | -1.05 | — | -1.11 | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -48.40 | -48.40 | -2.47 | -687.60 | -88.30 | -185.79 |
Net cash position: cash ($3M) exceeds total debt ($0)
MIRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MIRA Pharmaceuticals, Inc.'s current ratio of 3.99x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.36x to 3.99x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 3.99 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Quick Ratio | 3.99 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Cash Ratio | 3.92 | 3.92 | 8.25 | 0.26 | 2.57 | 0.04 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
MIRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MIRA Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $15M | $19M | $15M | $15M | $15M |
Peer Comparison
Compare MIRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MIRAYou | $40M | -2.0 | — | — | — | — | -238.9% | — | — |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 SILO | $2M | -0.4 | — | — | 91.9% | -6526.4% | -78.4% | -186.7% | — |
 LPCN | $13M | -1.4 | — | — | -334.3% | -524.7% | -54.3% | -64.7% | — |
 PSTV | $14M | -0.8 | — | — | 91.5% | -293.5% | -560.2% | — | — |
 ENVB | $132848 | -0.0 | — | — | — | — | -539.6% | — | — |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See MIRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MIRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MIRA vs ATAI
Side-by-side business, growth, and profitability comparison vs Atai Beckley N.V.
Start ComparisonMIRA — Frequently Asked Questions
Quick answers to the most common questions about buying MIRA stock.
What is MIRA Pharmaceuticals, Inc.'s P/E ratio?
MIRA Pharmaceuticals, Inc.'s current P/E ratio is -2.0x. This places it at the 50th percentile of its historical range.
What is MIRA Pharmaceuticals, Inc.'s ROE?
MIRA Pharmaceuticals, Inc.'s return on equity (ROE) is -238.9%. The historical average is -218.7%.
Is MIRA stock overvalued?
Based on historical data, MIRA Pharmaceuticals, Inc. is trading at a P/E of -2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.